1型糖尿病患者体内针对胰岛抗原2、谷氨酸脱羧酶和拓扑异构酶II的自身抗体。

Autoantibodies against IA-2, GAD, and topoisomerase II in type 1 diabetic patients.

作者信息

Chang Yih-Hsin, Shiau Ming-Yuh, Tsai Shih-Tzer, Lan Michael S

机构信息

School of Medical Technology, Chung Shan Medical University, Taichung, Taiwan, ROC.

出版信息

Biochem Biophys Res Commun. 2004 Jul 30;320(3):802-9. doi: 10.1016/j.bbrc.2004.05.215.

DOI:10.1016/j.bbrc.2004.05.215

PMID:15240119

Abstract

Prevalence of autoantibodies against IA-2 (IA-2A), glutamic acid decarboxylase (GADA), and type II DNA topoisomerase (TopIIA) of Taiwanese type 1 diabetes mellitus (T1DM) patients was investigated. Correlations of these autoantibodies with patients' clinical manifestations were also analyzed. Prevalence of IA-2A, GADA, and TopIIA in our patients was 23.6%, 47.1%, and 55.2%, respectively. Eighty percent of the IA-2A recognized the carboxyl terminus of the IA-2 protein tyrosine phosphatase-like domain. Average disease duration of IA-2A+ patients was significantly shorter than that of IA-2A- patients [3.76+/-0.42 vs. 4.98+/-0.34 years, p = 0.028]. Presence of GADA was correlated with the mean age of onset [10.82+/-0.76 vs. 8.38+/-0.77 years for GADA+ and GADA- patients, p = 0.026]. Patients with adolescent onset have higher GADA prevalence and better residual beta-cell functions. TopIIA and GADA are suggested to be better markers for Taiwanese T1DM patients because of their higher prevalence and persistence.

摘要

我们调查了台湾1型糖尿病（T1DM）患者中抗胰岛抗原-2（IA-2A）、谷氨酸脱羧酶（GADA）和II型DNA拓扑异构酶（TopIIA）自身抗体的患病率。我们还分析了这些自身抗体与患者临床表现之间的相关性。在我们的患者中，IA-2A、GADA和TopIIA的患病率分别为23.6%、47.1%和55.2%。80%的IA-2A识别IA-2蛋白酪氨酸磷酸酶样结构域的羧基末端。IA-2A阳性患者的平均病程显著短于IA-2A阴性患者[3.76±0.42岁对4.98±0.34岁，p = 0.028]。GADA的存在与平均发病年龄相关[GADA阳性和GADA阴性患者分别为10.82±0.76岁对8.38±0.77岁，p = 0.026]。青春期发病的患者GADA患病率更高，残余β细胞功能更好。由于TopIIA和GADA的患病率更高且持续存在，它们被认为是台湾T1DM患者更好的标志物。